SAM #FY26-0778

Procurement of Illumina NextSeq 1000 Sequencing System for AFMES DNA Operations

The Department of Defense, through the Armed Forces Medical Examiner System (AFMES) DNA Operations, is seeking to procure a high-throughput DNA sequencing system to support its mission of identifying missing service members from past conflicts. - Government Buyer: - Department of Defense - Armed Forces Medical Examiner System (AFMES) DNA Operations - OEM Highlight: - Illumina, Inc. is the sole source OEM specified for this requirement - Products/Services Requested: - Illumina NextSeq 1000 Sequencing System (quantity: 1) - Next-generation sequencing platform with integrated DNA-to-analysis workflow - Utilizes XLEAP-SBS chemistry - Supports flexible read lengths (2x50 bp to 2x300 bp) - Up to 120 Gb output per run, 400 million single reads per run - Run times between 8 and 42 hours - Integrated reagent cartridge, touchscreen interface, RFID tracking - Instrument control computer (Linux OS, 288 GB RAM, 3.8 TB SSD) - Dimensions: ≤55 cm W x 65 cm D x 60 cm H; Weight: ≤141 kg - Upgrade path to NextSeq 2000 - Unique/Notable Requirements: - System must be backward compatible with existing forensic assays - Must support increased mission sample workload - Sole source justification: Only Illumina, Inc. is considered technically acceptable, but capability statements from other vendors are invited - Replacement for end-of-life NextSeq 550 systems

Description

​​The Defense Health Agency Contracting Activity (DHACA) in Fort Detrick, MD intends to negotiate on a sole source basis (IAW RFO 12.102(a)) with ILLUMINA, INC 5200 Illumina Way, San Diego, CA 9212-4616 as the only responsible source that can provide the NextSeq 1000 Sequencing System.  This is a Presolicitation notice in accordance with RFO 5.101.

The equipment provided by ILLUMINA INC is the only source that provides DHACA with the NextSeq 1000 Sequencing System used at the Armed Forces Medical Examiner System DNA Operations (AFMES-DNA OPS) to support their mission.  Its fast, integrated DNA-to-analysis workflow allows for the rapid sequencing of targeted panels, whole mitochondrial genomes, and supports single nucleotide polymorphism (SNP) analysis in a single run.

This acquisition is being conducted under simplified acquisition procedures. There are no set-aside restrictions for this requirement. The intended procurement will be classified under North American Industry Classification System (NAICS) 334516 with a Small Business Size Standard of 1,000 employees. This presolicitation notice is not a request for competitive proposals and no solicitation document exists for this requirement. However, any parties interested in responding to this notice shall submit technical data, including cost, sufficient to determine capability in providing the same service. All capability statements received by closing of this notification of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  

Based on the above information, the only technically acceptable subscription can be provided by ILLUMINA INC .

Submit email capability statements (using PDF, MS Word, Excel attachments) to Alicia Maldonado Torres at alicia.maldonadotorres.civ@health.mil. Statements are due no later than 12:00 P.M. EST on 1 July 2026. No phone calls will be accepted.

View original listing